Publications by authors named "Jiao-e Zeng"

Claim this Profile
D
Diabetes remission in drug-naïve patients with type 2 diabetes after dorzagliatin treatment: A prospective cohort study.
Jiao'e Zeng, Shenglian Gan, Nianrong Mi, Yunfeng Liu, Xiaofei Su

Diabetes Obes Metab· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation analysis of serum IGF-1 and IL-6 and urinary albumin/creatinine ratio in patients with type 2 diabetic kidney disease.
Guan-Wen Liu, Jiao-E Zeng, Lan-Fang Li

Front Endocrinol (Lausanne)· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial.
Wenying Yang, Dalong Zhu, Shenglian Gan, Xiaolin Dong, Junping Su, Jiao'e Zeng

Nat Med· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial.
Dalong Zhu, Xiaoying Li, Jianhua Ma, Jiao'e Zeng, Shenglian Gan, Longyi Zeng

Nat Med· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Linong Ji, Jianhua Ma, Weiping Lu, Jingdong Liu, Jiao'e Zeng

J Diabetes Investig· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study.
Dalong Zhu, Shenglian Gan, Yu Liu, Jianhua Ma, Xiaolin Dong, Jiao'e Zeng, Longyi Zeng

Lancet Diabetes Endocrinol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Up-regulation of receptor interaction protein 140 promotes glucolipotoxicity-induced damage in MIN6 cells.
Li Jun Xue, Qi Huang, Jiao E Zeng, Hui Zhu, Cheng Yan Xu

Cell Mol Biol (Noisy-le-grand)· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SPLUNC1 Is a Significant Marker in Pleural Effusion from Lung Cancer Compared to Tuberculosis.
Jun L Xue, Ling Yi, Zhou H Yan, Xin Li, Xiao J Wang, Jiao E Zeng

Monoclon Antib Immunodiagn Immunother· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[The design and baseline characteristics of a phase III study to evaluate the efficacy and safety of alogliptin versus placebo in type 2 diabetes mellitus in Mainland China].
Chang-yu Pan, Wen-hui Li, Jiao-e Zeng, Cheng-jiang Li, Jin-kui Yang

Zhonghua Nei Ke Za Zhi· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis